BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28918915)

  • 1. A Life-Threatening Cause of Colitis.
    Jaswani TS; Grider DJ; Bern MJ
    Gastroenterology; 2018 Jan; 154(1):35-36. PubMed ID: 28918915
    [No Abstract]   [Full Text] [Related]  

  • 2. Flexible Sigmoidoscopy Rather than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis.
    Herlihy JD; Beasley S; Simmelink A; Maddukuri V; Amin A; Kamionek M; Jacobs C; Bossi K; Scobey M
    South Med J; 2019 Mar; 112(3):154-158. PubMed ID: 30830228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoscopic findings of ipilimumab-induced colitis.
    Satoh T; Ohno K; Kurokami T
    Dig Endosc; 2017 May; 29(3):388-389. PubMed ID: 28128877
    [No Abstract]   [Full Text] [Related]  

  • 4. Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy.
    Apostolova P; Unger S; von Bubnoff D; Meiss F; Becher B; Zeiser R
    N Engl J Med; 2020 Jan; 382(3):294-296. PubMed ID: 31940706
    [No Abstract]   [Full Text] [Related]  

  • 5. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
    Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
    J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
    [No Abstract]   [Full Text] [Related]  

  • 6. Diet-dependent toxicity of ipilimumab in metastatic melanoma.
    Majenka P; Hoffmann M; Rötzer I; Dimitrakopoulou-Strauss A; Koschny R; Longerich T; Enk A; Hassel JC
    Eur J Cancer; 2019 Jan; 106():220-224. PubMed ID: 30528806
    [No Abstract]   [Full Text] [Related]  

  • 7. Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients.
    Garcia-Neuer M; Marmarelis ME; Jangi SR; Luke JJ; Ibrahim N; Davis M; Weinberg J; Donahue H; Bailey N; Hodi FS; Buchbinder EL; Ott PA
    Cancer Immunol Res; 2017 Apr; 5(4):286-291. PubMed ID: 28373217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
    Hammami MB; Gill R; Thiruvengadam N; Oh DY; Beck K; Mahadevan U; Kattah MG
    Dig Dis Sci; 2019 Mar; 64(3):685-688. PubMed ID: 30778872
    [No Abstract]   [Full Text] [Related]  

  • 9. Ipilimumab-induced hypophysitis and ileocolitis: Serial pituitary MRI findings.
    Singh D; Hsu CC; Kwan GN; Bhuta S
    Neurol India; 2017; 65(1):165-166. PubMed ID: 28084260
    [No Abstract]   [Full Text] [Related]  

  • 10. [Ipilimumab induced colitis].
    Thielsen P; Svane IM
    Ugeskr Laeger; 2015 Nov; 177(46):V66773. PubMed ID: 26573945
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapy-induced colitis: Could it be ulcerative colitis?
    Moreno Moraleda I; Lázaro Sáez M; Diéguez Castillo C; Hernández Martínez Á
    Gastroenterol Hepatol; 2021 Jan; 44(1):28-29. PubMed ID: 32873419
    [No Abstract]   [Full Text] [Related]  

  • 12. Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab.
    Choe JH; Andonian BJ; Kim GJ; Salama AK
    Immunotherapy; 2016 Oct; 8(10):1163-7. PubMed ID: 27605066
    [No Abstract]   [Full Text] [Related]  

  • 13. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.
    Adler NR; Murray WK; Brady B; McCormack C; Pan Y
    Clin Exp Dermatol; 2018 Jun; 43(4):497-499. PubMed ID: 29396853
    [No Abstract]   [Full Text] [Related]  

  • 14. Ipilimumab prolongs survival in advanced melanoma.
    Burki TK
    Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
    Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
    [No Abstract]   [Full Text] [Related]  

  • 16. [Severe ipilimumab-induced ulcerative colitis remitting after infliximab therapy and secondary switching with pembrolizumab].
    Yelehe-Okouma M; Granel-Brocard F; Hudziak H; Schmutz JL; Gillet P
    Therapie; 2018; 73(3):291-293. PubMed ID: 29203065
    [No Abstract]   [Full Text] [Related]  

  • 17. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
    Hwang SJ; Carlos G; Wakade D; Sharma R; Fernandez-Penas P
    Melanoma Res; 2016 Aug; 26(4):417-20. PubMed ID: 27031538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
    Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Başsorgun I; Coşkun HŞ
    J Oncol Pharm Pract; 2016 Jun; 22(3):533-6. PubMed ID: 25694346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
    Tsiogka A; Jansky GL; Bauer JW; Koelblinger P
    Melanoma Res; 2017 Oct; 27(5):524-525. PubMed ID: 28858175
    [No Abstract]   [Full Text] [Related]  

  • 20. [Histoseminar on inflammatory bowel diseases (IBD): Case n
    Fléjou JF
    Ann Pathol; 2017 Aug; 37(4):298-301. PubMed ID: 28734677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.